m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05220
 [1]
Non-coding RNA LINC01615 HNRNPA1  lncRNA       miRNA   circRNA Direct Inhibition m6A modification G6PD G6PD hnRNPA1 : m6A sites
m6A Modification:
m6A Regulator Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1) READER
 Regulator Info 
m6A Target Glucose-6-phosphate dehydrogenase (G6PD)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator Long intergenic non-protein coding RNA 1615 (LINC01615) LncRNA View Details
Regulated Target Heterogeneous nuclear ribonucleoprotein A1 (HNRNPA1) View Details
Crosstalk Relationship ncRNA  →  m6A Inhibition
Crosstalk Mechanism ncRNAs directly impacts m6A modification through recruiting m6A regulator
Crosstalk Summary LINC01615 promoted Glucose-6-phosphate dehydrogenase (G6PD) expression by competitively binding with hnRNPA1 and facilitating G6PD pre-mRNA splicing.LINC01615 maintains cell survival in adaptation to nutrient starvation through the pentose phosphate pathway and modulates chemosensitivity in colorectal cancer
Responsed Disease Colorectal cancer ICD-11: 2B91
 Disease Info 
Responsed Drug Oxaliplatin
 Drug Info 
In-vitro Model
 SW480 Colon adenocarcinoma Homo sapiens CVCL_0546
HT29 Colon cancer Mus musculus CVCL_A8EZ
SW620 Colon adenocarcinoma Homo sapiens CVCL_0547
DLD-1 Colon adenocarcinoma Homo sapiens CVCL_0248
HCT 116 Colon carcinoma Homo sapiens CVCL_0291
LoVo Colon adenocarcinoma Homo sapiens CVCL_0399
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Glucose-6-phosphate dehydrogenase (G6PD) 6 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name Prasterone Approved [2]
Synonyms
Dehydroepiandrosterone; DHEA; 53-43-0; Dehydroisoandrosterone; Androstenolone; trans-Dehydroandrosterone; Psicosterone; Diandrone; Diandron; 3beta-hydroxyandrost-5-en-17-one; 17-Hormoforin; Prestara; 17-Chetovis; Andrestenol; 5-Dehydroepiandrosterone; Intrarosa; Siscelar plus; 5,6-Didehydroisoandrosterone; Dehydro-epi-androsterone; Prasteronum; 5,6-Dehydroisoandrosterone; Prasterona; Epiandrosterone, 5-dehydro-; Caswell No 051F; 5,6-Dehydroisoandrostorone
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 6200 nM
External Link
CID: 5881
TTD: D0K0EK
DrugBank: DB01708
 Compound Name EPIANDROSTERONE Phase 3 [3]
Synonyms
481-29-8; trans-Androsterone; Isoandrosterone; 3Beta-hydroxy-5alpha-androstan-17-one; 3beta-Hydroxyetioallocholan-17-one; epi-andosterone; 5alpha-Androstan-3beta-ol-17-one; iso-Androsterone; d-Epiandrosterone; UNII-8TR252Z538; 3-Epiandrosterone; (3beta,5alpha)-3-hydroxyandrostan-17-one; CHEMBL272195; 3beta-Hydroxy-androstan-17-one; CHEBI:541975; QGXBDMJGAMFCBF-LUJOEAJASA-N; Androsterone, epi-; NSC 93996; MFCD00064134; 8TR252Z538; ST072176; Androstan-17-one, 3-hydroxy-, (3b,5a)-; epi-Androsterone; C19H30O2
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 3000 nM
External Link
CID: 441302
TTD: D0O8FW
 Compound Name CBF-BS2 Discontinued in Phase 2 [4]
Synonyms
KSB-302
    Click to Show/Hide
MOA Modulator
External Link
TTD: D05JCG
 Compound Name Hydroxyacetic Acid Investigative [5]
Synonyms
glycolic acid; 2-Hydroxyacetic acid; 79-14-1; Glycollic acid; Hydroxyethanoic acid; Acetic acid, hydroxy-; glycolate; Caswell No. 470; alpha-Hydroxyacetic acid; Kyselina glykolova; Kyselina glykolova [Czech]; Kyselina hydroxyoctova; HOCH2COOH; 2-Hydroxyethanoic acid; Kyselina hydroxyoctova [Czech]; Glycocide; EPA Pesticide Chemical Code 000101; GlyPure; HSDB 5227; NSC 166; Acetic acid, 2-hydroxy-; AI3-15362; UNII-0WT12SX38S; GlyPure 70; BRN 1209322; GLYCOLLATE; C2H4O3; Acetic acid, hydroxy-, homopolymer; EINECS 201-
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 757
TTD: D01HNP
DrugBank: DB03085
 Compound Name Metazamide Investigative [2]
Synonyms
UNII-T3Y0F5VOB8; 14058-90-3; GPA-878; T3Y0F5VOB8; Metazamidum; 1-(4-methoxyphenyl)-5-methyl-2,3-dihydro-1H-imidazol-2-one; Metazamide [INN]; Metazamid; GPA 878; AC1L1B4L; 3-(4-methoxyphenyl)-4-methyl-1H-imidazol-2-one; 1-(4-Methoxyphenyl)-5-methyl-4-imidazolin-2-on; ZINC472; SCHEMBL193544; CHEMBL2104723; DTXSID80161441; MolPort-027-352-367; AKOS017548002; 1-(p-Methoxyphenyl)-5-methyl-4-imidazolin-2-one; 4-Imidazolin-2-one, 1-(4-methoxyphenyl)-5-methyl-
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 26433
TTD: D0FF3D
 Compound Name 2'-Monophosphoadenosine 5'-Diphosphoribose Investigative [5]
Synonyms
53-59-8; Cozymase II; Codehydrogenase II; TPN (nucleotide); Codehydrase II; Nadide phosphate; NAD phosphate; EINECS 200-178-1; BRN 3885115; nicotinamide adenine dinucleotide phosphate; CHEBI:44409; beta-NADP; Adenosine 5'-(trihydrogen diphosphate), 2'-(dihydrogen phosphate), P'-5'-ester with 3-(aminocarbonyl)-1-beta-D-ribofuranosylpyridinium, inner salt; beta-TPN; TPN-ox; nadp nicotinamide-adenine-dinucleotide phosphate; Adenosine 5'-(trihydrogen diphosphate), 2'-(dihydrogen p
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 46936685
TTD: D0J2FY
Heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1) 15 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name ISIS 112000 Investigative [6]
External Link
TTD: D00LSM
 Compound Name ISIS 112022 Investigative [6]
External Link
TTD: D00SQD
 Compound Name ISIS 112019 Investigative [6]
External Link
TTD: D04XOE
 Compound Name ISIS 112005 Investigative [6]
External Link
TTD: D06QZK
 Compound Name ISIS 112002 Investigative [6]
External Link
TTD: D07FSX
 Compound Name ISIS 112023 Investigative [6]
External Link
TTD: D07RUF
 Compound Name ISIS 111992 Investigative [6]
External Link
TTD: D0D9OL
 Compound Name ISIS 112003 Investigative [6]
External Link
TTD: D0GD1R
 Compound Name ISIS 111997 Investigative [6]
External Link
TTD: D0H0YU
 Compound Name ISIS 112004 Investigative [6]
External Link
TTD: D0H6OL
 Compound Name ISIS 112001 Investigative [6]
External Link
TTD: D0N7OK
 Compound Name ISIS 112024 Investigative [6]
External Link
TTD: D0QU6S
 Compound Name ISIS 112020 Investigative [6]
External Link
TTD: D0T0XZ
 Compound Name ISIS 111993 Investigative [6]
External Link
TTD: D0Y4TS
 Compound Name ISIS 112021 Investigative [6]
External Link
TTD: D0Z4RI
2B91: Colorectal cancer 25 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name Retifanlimab Approved [7]
Synonyms
INCMGA0012; Retifanlimab
    Click to Show/Hide
External Link
TTD: D0PG5O
 Compound Name Aflibercept Approved [8]
Synonyms
Ziv-Aflibercept; Zaltrap (TN); VEGF Trap; VEGF Trap-Eye
    Click to Show/Hide
External Link
TTD: D0C9ET
 Compound Name Regorafenib Approved [9]
Synonyms
755037-03-7; BAY 73-4506; Regorafenibum; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; BAY73-4506; Regorafenib (BAY 73-4506); UNII-24T2A1DOYB; 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide; BAY-73-4506; 24T2A1DOYB; CHEMBL1946170; CHEBI:68647; Stivarga (TN); BAY73-4506 hydrochloride; Regorafenib [USAN:INN]
    Click to Show/Hide
External Link
CID: 11167602
TTD: D09GDD
DrugBank: DB08896
 Compound Name Bevacizumab Approved [10]
Synonyms
Bevacizumab (ophthalmic slow-release tissue tablet)
    Click to Show/Hide
External Link
TTD: D04KBL
 Compound Name SYM-004 Phase 3 [10]
Synonyms
Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen
    Click to Show/Hide
External Link
TTD: D0CR8H
 Compound Name Bevacizumab + Erlotinib Phase 3 [11]
External Link
TTD: D09BKY
 Compound Name CPI-613 Phase 3 [10]
Synonyms
95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874
    Click to Show/Hide
External Link
CID: 24770514
TTD: D07NVI
DrugBank: DB12109
 Compound Name Bevacizumab Approved [8]
External Link
TTD: D0FX3U
 Compound Name AlloStim Phase 2/3 [12]
Synonyms
AlloStim (TN)
    Click to Show/Hide
External Link
TTD: D0B3CC
 Compound Name Sibrotuzumab Phase 2 [13]
External Link
TTD: DVX3H0
 Compound Name CV301 Phase 2 [14]
External Link
TTD: D9LT5G
 Compound Name Efatutazone Phase 2 [15]
Synonyms
Inolitazone; 223132-37-4; 5-[[4-[[6-(4-amino-3,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy]phenyl]methyl]-2,4-Thiazolidinedione; Efatutazone [INN]; RS5444; CS-7017; SCHEMBL3246054; CHEMBL3545280; JCYNMRJCUYVDBC-UHFFFAOYSA-N; Efatutazone;CS-7017;RS5444; BCP07478; AKOS030526729; DB11894; CS-0778; KB-77905; DA-07988; HY-14792; QC-10456; 4CA-1384; FT-0737589; 5-[4-[6-(4-amino-3 ,5-dimethylphenoxy)-1-methyl-1H-benzimidazol-2-ylmethoxy]benzyl]thiazolidine-2,4-dione
    Click to Show/Hide
External Link
CID: 9832447
TTD: D0Y8NZ
DrugBank: DB11894
 Compound Name LOR-2040 Phase 2 [16]
External Link
TTD: D0I7NG
 Compound Name RG7221 Phase 2 [17]
External Link
TTD: D06FTM
 Compound Name PEG-SN38 Phase 2 [18]
Synonyms
EZN-2208
    Click to Show/Hide
External Link
CID: 59443782
TTD: D05UFP
 Compound Name MEGF0444A Phase 2 [19]
External Link
TTD: D01LES
 Compound Name Encapsulated cell therapy Phase 1/2 [20]
External Link
TTD: D0XY8C
 Compound Name AB928 Phase 1/2 [21]
External Link
CID: 135242184
TTD: D04UBI
 Compound Name MGD007 Phase 1 [17]
External Link
TTD: D00PEN
 Compound Name BNC-101 Phase 1 [22]
External Link
TTD: DD6AZ5
 Compound Name Navicixizumab Phase 1 [10]
External Link
TTD: D00IVN
 Compound Name RG7160 Discontinued in Phase 2 [23]
External Link
TTD: D0E2CQ
 Compound Name Nimesulide Terminated [24]
Synonyms
51803-78-2; N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide; Mesulid; Flogovital; Sulidene; Nimed; R-805; 4-NITRO-2-PHENOXYMETHANESULFONANILIDE; Nisulid; Nimesulidum [INN-Latin]; Nimesulida [INN-Spanish]; R 805; UNII-V4TKW1454M; 4-Nitro-2-phenoxy-methanesulfonanilide; 4'-Nitro-2'-phenoxymethanesulfonanilide; Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)-; EINECS 257-431-4; 4'-Nitro-2'-phenoxymethansulfonanilid; BRN 2421175; CHEMBL56367; MLS000069680; V4TKW1454M; Methanesulfonanilide, 4'-nitro-2'-phenoxy-; CHEBI:44445; Dulanermin
    Click to Show/Hide
External Link
CID: 4495
TTD: D0C0JT
DrugBank: DB04743
 Compound Name Saracatinib Phase 2 [25]
External Link
CID: 10302451
TTD: D05YTN
DrugBank: DB11805
 Compound Name G3139 + Irinotecan Investigative [26]
External Link
CID: 91865905
TTD: D05IAN
References
Ref 1 LINC01615 maintains cell survival in adaptation to nutrient starvation through the pentose phosphate pathway and modulates chemosensitivity in colorectal cancer. Cell Mol Life Sci. 2022 Dec 28;80(1):20. doi: 10.1007/s00018-022-04675-7.
Ref 2 Glucose utilization and activity of glucose-6-phosphate dehydrogenase, isocitrate dehydrogenase and malate dehydrogenase in rat erythrocytes after treatment with tuberculostatic agents. Vopr Med Khim. 1986 Sep-Oct;32(5):32-5.
Ref 3 Inhibition of Trypanosoma brucei glucose-6-phosphate dehydrogenase by human steroids and their effects on the viability of cultured parasites. Bioorg Med Chem. 2009 Mar 15;17(6):2483-9.
Ref 4 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007279)
Ref 5 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
Ref 6 US patent application no. 6,165,789, Antisense modulation of hnRNP A1 expression.
Ref 7 Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730.
Ref 8 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 9 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5891).
Ref 10 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 11 ClinicalTrials.gov (NCT00130728) A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer
Ref 12 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 13 ClinicalTrials.gov (NCT02198274) Intravenous BIBH 1 in Patients With Metastatic Colorectal Cancer. U.S. National Institutes of Health.
Ref 14 ClinicalTrials.gov (NCT03547999) A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC. U.S. National Institutes of Health.
Ref 15 ClinicalTrials.gov (NCT02152137) Efatutazone With Paclitaxel Versus Paclitaxel Alone in Treating Patients With Advanced Anaplastic Thyroid Cancer. U.S. National Institutes of Health.
Ref 16 ClinicalTrials.gov (NCT00087165) GTI-2040, Docetaxel, and Prednisone in Treating Patients With Prostate Cancer. U.S. National Institutes of Health.
Ref 17 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 18 ClinicalTrials.gov (NCT01036113) A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer. U.S. National Institutes of Health.
Ref 19 ClinicalTrials.gov (NCT00909740) A Study of the Safety and Pharmacokinetics of MEGF0444A Administered to Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
Ref 20 VC-01's Path to the Clinic. Viacyte. 2015.
Ref 21 ClinicalTrials.gov (NCT04660812) An Open Label Study Evaluating the Efficacy and Safety of AB928 Based Treatment Combinations in Patients With Metastatic Colorectal Cancer.. U.S. National Institutes of Health.
Ref 22 ClinicalTrials.gov (NCT02726334) A Phase I, Dose Escalation Study of BNC101 in Patients With Metastatic Colorectal Cancer.. U.S. National Institutes of Health.
Ref 23 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029052)
Ref 24 Clinical pipeline report, company report or official report of Genentech (2011).
Ref 25 Phase II Study of Saracatinib (AZD0530) in Patients With Previously Treated Metastatic Colorectal Cancer. Invest New Drugs. 2015 Aug;33(4):977-84.
Ref 26 Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.